Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.15420/icr.2015.10.2.109 http://scihub22266oqcxt.onion/10.15420/icr.2015.10.2.109 C5808629!5808629!29588685     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=29588685&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Interv+Cardiol 2015 ; 10 (2): 109-11 Nephropedia Template TP {{tp|p=29588685|t=2015. Real World Outcomes of Left Atrial Appendage Occlusion |pdf=|usr=}}{{29588685}} gab.com Text Real World Outcomes of Left Atrial Appendage Occlusion JO: Interv Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=29588685 #FOAvip Percutaneous left atrial appendage occlusion (LAAO) is a device-based therapy for the prevention of stroke in patients with non-valvular atrial fibrillation (AF). Recently, the Watchman device (Boston Scientific, St Paul, MN, US) was approved in the US by the Food and Drug Administration (FDA) based on the results of two randomised clinical trials that evaluated LAAO in patients eligible for oral anticoagulation (OAC) therapy. However, in real-word clinical practice LAAO is typically offered to patients ineligible for OAC therapy, as they appear to have limited treatment options and consequently worse prognosis. Although LAAO has shown favourable clinical outcomes in OAC-ineligible patients in single or multicentre observational studies, these results need to be confirmed in randomised clinical trials. Twit Text FOAVip Real World Outcomes of Left Atrial Appendage Occlusion ????Interv Cardiol http://www.kidney.de/pget.php?&tw=1&pmid=29588685 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29588685 #FOAvip English Wikipedia <ref>{{Cite pmid|29588685}}</ref> Real World Outcomes of Left Atrial Appendage Occlusion #MMPMID29588685 Tzikas A; Mylotte D; Bergmann M Interv Cardiol 2015[May]; 10 (2): 109-11 PMID29588685show ga Percutaneous left atrial appendage occlusion (LAAO) is a device-based therapy for the prevention of stroke in patients with non-valvular atrial fibrillation (AF). Recently, the Watchman device (Boston Scientific, St Paul, MN, US) was approved in the US by the Food and Drug Administration (FDA) based on the results of two randomised clinical trials that evaluated LAAO in patients eligible for oral anticoagulation (OAC) therapy. However, in real-word clinical practice LAAO is typically offered to patients ineligible for OAC therapy, as they appear to have limited treatment options and consequently worse prognosis. Although LAAO has shown favourable clinical outcomes in OAC-ineligible patients in single or multicentre observational studies, these results need to be confirmed in randomised clinical trials. äReal World Outcomes of Left Atrial Appendage Occlusion (epmc).pdf DeepDyve Pubget Overpricing